<DOC>
	<DOCNO>NCT00096148</DOCNO>
	<brief_summary>Drugs use chemotherapy , idarubicin cytarabine , work different way stop cancer cell divide stop grow die . Bevacizumab may stop growth cancer stop blood flow leukemic cell bone marrow . Giving idarubicin cytarabine bevacizumab may kill cancer cell . It yet know whether give idarubicin together cytarabine effective without bevacizumab treat acute myeloid leukemia . This randomized phase II trial study well give idarubicin cytarabine together bevacizumab work compare idarubicin cytarabine alone treat patient newly diagnose acute myeloid leukemia</brief_summary>
	<brief_title>Idarubicin Cytarabine With Without Bevacizumab Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare activity idarubicin cytarabine without bevacizumab patient newly diagnose acute myeloid leukemia . II . Compare proportion patient survive remain first complete remission ( CR ) one year achieve CR treatment regimen . SECONDARY OBJECTIVES : I . Compare safety regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( &lt; 45 v 45 59 ) , cytogenetics ( normal v -5/-7 v ) , flt 3 status ( normal v mutate ) , type acute myeloid leukemia ( AML ) ( de novo v secondary [ arise cytotoxic therapy antecedent hematologic disorder , define document abnormality blood count &gt; = 3 month diagnosis AML ] . Patients require treatment cytogenetics flt 3 status know ( e.g. , patient WBC &gt; 50,000 OR organ dysfunction think due blast infiltration ) stratify accord age type AML . Induction therapy : Patients randomize 1 2 treatment arm . Arm I : Patients receive idarubicin IV 1 hour day 1-3 cytarabine IV continuously 24 hour day 1-4 . Arm II : Patients receive idarubicin cytarabine arm I . Patients also receive bevacizumab* IV 30-90 minute day 1 . Patients achieve complete remission ( CR ) first induction course may receive second induction course approximately 28 days* later . Patients achieve CR 2 course remove study . NOTE : *Patients arm II receive bevacizumab , independently chemotherapy administration schedule , every 21 day 1 year CR date . Post-CR therapy : All patient receive 4 post-CR chemotherapy course approximately every 28 day absence disease progression unacceptable toxicity . Course 1 : Patients receive cytarabine IV continuously 24 hour day 1-5 . Course 2 4 : Patients receive idarubicin IV 1 hour cytarabine IV continuously 24 hour day 1-4 . Course 3 : Patients receive idarubicin IV 1 hour cytarabine IV continuously 24 hour day 1-2 . After completion 4 post-CR chemotherapy course , patient arm I induction therapy receive therapy . Patients arm II induction therapy continue receive bevacizumab describe above.After completion study treatment , patient follow every 3 month 2 year . PROJECTED ACCRUAL : A total 60-120 patient ( 30-60 per treatment arm ) accrue study within 12-30 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Newly diagnose acute myeloid leukemia ( AML ) No acute promyelocytic leukemia None follow cytogenetic abnormalities* : ( 8 ; 21 ) ( 16 ; 16 ) inv ( 16 ) No history clinical evidence primary brain tumor brain metastasis Performance status ECOG 02 No bleed diathesis coagulopathy ( unless relate AML ) Bilirubin ≤ 2.0 time upper limit normal ( ULN ) ALT ≤ 2.5 time ULN Creatinine ≤ 2.0 time ULN No proteinuria No 1 g protein 24hour urine collection LVEF ≥ 50 % No uncontrolled hypertension No New York Heart Association class IIIV congestive heart failure No serious cardiac arrhythmia require medication No peripheral vascular disease ≥ grade II No stroke within past 6 month No arterial thromboembolic event within past 6 month , include follow : Transient ischemic attack Cerebrovascular accident Myocardial infarction Unstable angina No clinically significant cardiovascular disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 34 month study participation No serious nonhealing wound ulcer bone fracture No uncontrolled infection No significant traumatic injury within past 28 day No known hypersensitivity Chinese hamster ovary cell product recombinant human antibodies No history clinical evidence CNS disease ( e.g. , seizure control standard medical therapy ) Prior concurrent transfusion hematopoietic growth factor AML allow No concurrent prophylactic hematopoietic colonystimulating factor Prior concurrent hydroxyurea AML allow More 28 day since prior major surgery open biopsy No concurrent major surgery No prior therapy AML No concurrent fulldose anticoagulation therapy Concurrent prophylactic anticoagulation ( e.g . lowdose warfarin maintain patency permanent indwell IV catheter ) allow provide INR &lt; 1.5 No concurrent anticancer therapies No concurrent investigational cytotoxic agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>